Caricamento...
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
OBJECTIVE: In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key phase 3 trials of tyrosine kinase i...
Salvato in:
| Pubblicato in: | Daru |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7214547/ https://ncbi.nlm.nih.gov/pubmed/31900888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40199-019-00321-z |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|